The emerging role of nimotuzumab in the treatment of non-small cell lung cancer

References

• JemalASiegelRWardECancer statistics, 2008CA Cancer J Clin2008582719618287387
   PubMed Web of Science ®Google Scholar
• FryWAPhillipsJLMenckHRTen-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base reportCancer19998691867187610547562
   PubMed Web of Science ®Google Scholar
• EdwardsBKBrownMLWingoPAAnnual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatmentJ Natl Cancer Inst200597191407142716204691
   PubMed Web of Science ®Google Scholar
• JemalAThunMJRiesLAAnnual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco controlJ Natl Cancer Inst2008100231672169419033571
   PubMed Web of Science ®Google Scholar
• TowfighiAOvbiageleBSaverJLTherapeutic milestone: stroke declines from the second to the third leading organ- and disease-specific cause of death in the United StatesStroke201041349950320075347
   PubMed Web of Science ®Google Scholar
• EttingerDSAkerleyWBeplerGNon-small cell lung cancerJ Natl Compr Canc Netw20086322826918377844
   PubMedGoogle Scholar
• EmeryIFBattelliCAuclairPLCarrierKHayesDMResponse to gefitinib and erlotinib in non-small cell lung cancer: a restrospective studyBMC Cancer2009933319765296
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyNon-small cell lung cancer survival rates by stage Available from: http://www.cancer.org/Cancer/Lung-Cancer-Non-SmallCell/DetailedGuide/lung-cancer-non-small-cell-survival-rates. Published 2009Accessed Jul 13, 2010
   Google Scholar
• MolinaJRYangPCassiviSDSchildSEAdjeiAANon-small cell lung cancer: epidemiology, risk factors, treatment, and survivorshipMayo Clin Proc200883558459418452692
   PubMed Web of Science ®Google Scholar
• LuHSChaiJJLiMHuangBRHeCHBiRCCrystal structure of human epidermal growth factor and its dimerizationJ Biol Chem200127637349133491711438527
   PubMed Web of Science ®Google Scholar
• BennettCFMirejovskyDCrookeRMStructural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in cultureJ Drug Target1998531491629606005
   PubMed Web of Science ®Google Scholar
• WoodburnJRThe epidermal growth factor receptor and its inhibition in cancer therapyPharmacol Ther1999822–324125010454201
   PubMed Web of Science ®Google Scholar
• GrandisJRSokJCSignaling through the epidermal growth factor receptor during the development of malignancyPharmacol Ther2004 1021374615056497
   PubMed Web of Science ®Google Scholar
• LuZJiangGBlume-JensenPHunterTEpidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinaseMol Cell Biol2001 21124016403111359909
   PubMed Web of Science ®Google Scholar
• KassisJLauffenburgerDATurnerTWellsATumor invasion as dysregulated cell motilitySemin Cancer Biol200111210511711322830
   PubMed Web of Science ®Google Scholar
• RiveraFVega-VillegasMELopez-BreaMFCetuximab, its clinical use and future perspectivesAnticancer Drugs20081929911318176106
   PubMed Web of Science ®Google Scholar
• PaoWMillerVZakowskiMEGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProc Natl Acad Sci U S A200410136133061331115329413
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small- cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• NicholsonRIGeeJMWHarperMEEGFR and cancer prognosisEur J Cancer200137 Suppl 4S9S1511597399
   PubMed Web of Science ®Google Scholar
• NavolanicPMSteelmanLSMcCubreyJAEGFR family signaling and its association with breast cancer development and resistance to chemotherapy (review)Int J Oncol200322223725212527919
   PubMed Web of Science ®Google Scholar
• AkashiYOkamotoIIwasaTEnhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor statusBr J Cancer200898474975518253126
   PubMed Web of Science ®Google Scholar
• FukuokaMYanoSGiacconeGMulti-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancerJ Clin Oncol200321122237224612748244
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005 353212313216014882
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience2004 30456761497150015118125
   PubMed Web of Science ®Google Scholar
• PriceDKFiggWDMutations in the EGFR: the importance of genotypingCancer Biol Ther20043543443515254431
   PubMed Web of Science ®Google Scholar
• HoCMurrayNLaskinJMeloskyBAndersonHBebbGAsian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North AmericaLung Cancer200549222523115925429
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936110 94795719692680
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• GiacconeGHerbstRSManegoldCGefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1J Clin Oncol200422577778414990632
   PubMed Web of Science ®Google Scholar
• PloskerGLFiggittDPRituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemiaDrugs2003638 80384312662126
   PubMed Web of Science ®Google Scholar
• FerraraNHillanKJNovotnyWBevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapyBiochem Biophys Res Commun2005333232833515961063
   PubMed Web of Science ®Google Scholar
• LiSSchmitzKRJeffreyPDWiltziusJJKussiePFergusonKMStructural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell20057430131115837620
   PubMed Web of Science ®Google Scholar
• KimSGrandisJRRinaldoATakesRPFerlitoAEmerging perspectives in epidermal growth factor receptor targeting in head and neck cancerHead Neck200830566767418383530
   PubMed Web of Science ®Google Scholar
• MateoCMorenoEAmourKLombarderoJHarrisWPerezRHumanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activityImmunotechnology19973171819154469
   PubMedGoogle Scholar
• TalaveraAMartínezCFriemannRModeling the interaction between the anti-tumor antibody h-R3 and its target, the epidermal growth factor receptor Available from: www.ymbiosciences.com/upload_files/pub_nimo_oslo_2007_talavera.pdf2007
   Google Scholar
• ArteagaMELedonNCasacoASystemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumabCancer Biol Ther2007 691390139517827980
   PubMed Web of Science ®Google Scholar
• CrombetTTorresLNeningerECatalaMSolanoMEPereraAPharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancerJ Immunother200326213914812616105
   PubMed Web of Science ®Google Scholar
• Diaz MiqueliABlancoRGarciaBBiological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinitiesHybridoma (Larchmt)200726642343118158788
   PubMedGoogle Scholar
• Crombet-RamosTRakJPerezRViloria-PetitAAntiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibodyInt J Cancer2002101656757512237899
   PubMed Web of Science ®Google Scholar
• Viloria-PetitACrombetTJothySAcquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesisCancer Res200161135090510111431346
   PubMed Web of Science ®Google Scholar
• BaumannMKrauseMDikomeyEEGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanismsRadiother Oncol200783323824817502118
   PubMed Web of Science ®Google Scholar
• BierHHoffmannTHaasIvan LieropAAnti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neckCancer Immunol Immunother1998463 1671739625540
   PubMed Web of Science ®Google Scholar
• YM_BioSciencesNimotuzumab: Science Available from: http://www.ymbiosciences.com/products/nimotuzumab/science.php. Published 2010
   Google Scholar
• BolandWKBebbGNimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicityExpert Opin Biol Ther2009991199120619624281
   PubMed Web of Science ®Google Scholar
• YouBBradeAMagalhaesJMA dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignanciesInvest New Drugs201058 [Epub ahead of print]
   Web of Science ®Google Scholar
• WinquistENabidASicheriDA phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT)Proc Am Soc Clin Oncol200221 Abstract 926
   Google Scholar
• RojoFGraciasEVillenaNPharmacodynamic study of nimotuzumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN): a SENDO Foundation studyJ Clin Oncol200826 Abstract 607018165637
   PubMed Web of Science ®Google Scholar
• ReddyBKVidyasagarMShenoyKNimotuzumab (h-R3) in combination with chemoradiotherapy and radiotherapy in the treatment of squamous cell carcinoma of head and neck (SCCHN) Available from: http://astro2007.abstractsnet.com/handouts/500467_Biocon_h-R3.pdf2007
   Google Scholar
• RodriguezMORiveroTCdel Castillo BahiDNimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neckCancer Biol Ther20109534334920448462
   PubMed Web of Science ®Google Scholar
• CasacoALopezGGarciaIPhase I single-dose study of intracavitary-administered nimotuzumab labeled with 188 Re in adult recurrent high-grade gliomaCancer Biol Ther20087333333918094616
   PubMed Web of Science ®Google Scholar
• LamCBouffetEBartelsUNimotuzumab in pediatric gliomaFuture Oncol2009591349136119903064
   PubMed Web of Science ®Google Scholar
• ReddyBKVidyasagarMSKoteshwarRA phase IIb 4-arm open-label randomized study to assess the safety and efficacy of h-R3 monoclonal antibody against EGFR in combination with chemo-radiation therapy or radiation therapy in patients with advanced (stage III or IVA) inoperable head and neck cancerJ Clin Oncol20092715s Suppl Abstract 6041
   Google Scholar
• RamakrishnanMSEswaraiahACrombetTNimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originMAbs200911414820046573
   PubMed Web of Science ®Google Scholar
• YM_BioSciencesNimotuzumab: Clinical Trials Available from: http://www.ymbiosciences.com/products/nimotuzumab/clinical_trials.phpAccessed Jun 8, 2010
   Google Scholar
• BebbGSmithCRorkeSPhase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapyCancer Chemother Pharmacol2010620 [Epub ahead of print]
   Web of Science ®Google Scholar
• ChoiHJSohnJHLeeCGA phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean resultsLung Cancer201055 [Epub ahead of print]
   Web of Science ®Google Scholar
• FairchildAHarrisKBarnesEPalliative thoracic radiotherapy for lung cancer: a systematic reviewJ Clin Oncol20082624 4001401118711191
   PubMed Web of Science ®Google Scholar
• MaciasANeningerESantiestebanEPreliminary results of a phase II clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer (NSCLC) and unresectable brain metastasesPaper presented at: EORTC-NCI-AACR Annual Meeting2008Geneva, Switzerland
   Google Scholar
• AgeroALDuszaSWBenvenuto-AndradeCBusamKJMyskowskiPHalpernACDermatologic side effects associated with the epidermal growth factor receptor inhibitorsJ Am Acad Dermatol200655465767017010747
   PubMed Web of Science ®Google Scholar
• van CutsemEPeetersMSienaSOpen-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancerJ Clin Oncol200725131658166417470858
   PubMed Web of Science ®Google Scholar
• HuJCSadeghiPPinter-BrownLCYasharSChiuMWCutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and managementJ Am Acad Dermatol200756231732617141360
   PubMed Web of Science ®Google Scholar
• GiroCBergerBBolkeEHigh rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutesRadiother Oncol2009 90216617118977050
   PubMed Web of Science ®Google Scholar
• MerlanoMOccelliMReview of cetuximab in the treatment of squamous cell carcinoma of the head and neckTher Clin Risk Manag20073587187618473010
   PubMedGoogle Scholar
• MerlanoMGarroneOTreatment of advanced head and neck cancer with cetuximabInt J Biol Markers2007221 Suppl 4S71S7617520584
   PubMed Web of Science ®Google Scholar
• BonnerJAAngKMore on severe cutaneous reaction with radiotherapy and cetuximabN Engl J Med20073571818721873; author reply 187317978301
   PubMed Web of Science ®Google Scholar
• CrombetTFigueredoJCatalaMTreatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trialCancer Biol Ther20065437537916575203
   PubMed Web of Science ®Google Scholar
• RojoFGraciasEVillenaNPharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation studyClin Cancer Res20101682474248220371675
   PubMed Web of Science ®Google Scholar
• TejparSPiessevauxHClaesKMagnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective studyLancet Oncol20078538739417466895
   PubMed Web of Science ®Google Scholar
• GiustiRMCohenMHKeeganPPazdurRFDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancerOncologist200914328429019282350
   PubMed Web of Science ®Google Scholar
• CrombetTOsorioMCruzTUse of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patientsJ Clin Oncol20042291646165415117987
   PubMed Web of Science ®Google Scholar
• TikhomirovIGarridoGYangEShermanIPerezRBivalent binding properties of epidermal growth factor receptor (EGFR) targeted monoclonal antibodies: factors contributing to differences in observed clinical profilesAACR Cancer Clinical Trials and Personalized Medicine2008 Abstract A36
   Google Scholar
• GarridoGRabasaAGraciaEBinding properties of the anti-EGFR monoclonal antibody, nimotuzumab, limit its interaction with the EGFR in renal and epidermal cellsPaper presented at: AACR 100th Annual Meeting2009San Diego, CA Abstract 2763
   Google Scholar
• ValeCTierneyJFMeadeAImpact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs)J Clin Oncol200927Suppl 154122 In: Proceedings of ASCO Annual Meeting. 2009; Alexandria, VA. Abstract 4122
   Web of Science ®Google Scholar
• AmadoRGWolfMPeetersMWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol200826101626163418316791
   PubMed Web of Science ®Google Scholar
• KarapetisCSKhambata-FordSJonkerDJK-ras mutations and benefit from cetuximab in advanced colorectal cancerN Engl J Med2008359171757176518946061
   PubMed Web of Science ®Google Scholar
• ShahAMChenEJonkerDA Phase II clinical trial of nimotuzumab, an EGFR monoclonal antibody (MAb), in metastatic colorectal cancer (mCRC)J Clin Oncol2009 In: Proceedings of ASCO GI symposium; 2009; Alexandria, VA. Abstract 358
   Google Scholar
• PirkerRPereiraJRSzczesnaACetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet200937396741525153119410716
   PubMed Web of Science ®Google Scholar
• O’ByrneKJBondarenkoIBarriosCMolecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer(NSCLC): data from the FLEX studyJ Clin Oncol200927Suppl 15 Abstract 8007
   Web of Science ®Google Scholar
• LoriotYMordantPDeutschEOlaussenKASoriaJCAre RAS mutations predictive markers of resistance to standard chemotherapy?Nat Rev Clin Oncol20096952853419597509
   PubMed Web of Science ®Google Scholar
• LinardouHDahabrehIJKanaloupitiDAssessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancerLancet Oncol200891096297218804418
   PubMed Web of Science ®Google Scholar
• López-AlbaiteroASteveCLMorganSRole of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cellsCancer Immunol Immunother2009 581118551864
   Web of Science ®Google Scholar
• BibeauFLopez-CrapezEDi FioreFImpact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecanJ Clin Oncol20092771122112919164213
   PubMed Web of Science ®Google Scholar
• Oden-GangloffADi FioreFBibeauFTP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapyBr J Cancer200910081330133519367287
   PubMed Web of Science ®Google Scholar
• MackPCGandaraDROmoriAKRAS mutation analysis in NSCLC versus colorectal cancer (CRC): implications for EGFR-directed therapiesPaper presented at: IASLC World Conference on Lung Cancer2009San Francisco, CA
   Google Scholar
• YangPAllenMSAubryMCClinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003Chest2005128145246216002972
   PubMed Web of Science ®Google Scholar
• Diaz MiqueliARolffJLemmMFichtnerIPerezRMonteroERadiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodiesBr J Cancer20091006 95095819293809
   PubMed Web of Science ®Google Scholar
• KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med2005352878679215728811
   PubMed Web of Science ®Google Scholar
• KimH-PHanS-WKimS-HCombined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cellsMol Cancer Ther20087360761518347147
   PubMed Web of Science ®Google Scholar
• MorgilloFKimW-YKimESCiardielloFHongWKLeeH-YImplication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinibClin Cancer Res20071392795280317473213
   PubMed Web of Science ®Google Scholar
• KaulfuβSBurfeindPGaedckeJScharfJ-GDual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosisMol Cancer Ther20098482183319372555
   PubMed Web of Science ®Google Scholar
• BartolomeRAFerreiroSMiquilena-ColinaMEThe chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungsAm J Pathol2009 17426021219147814
   PubMed Web of Science ®Google Scholar
• PuntCJATolJMore is less – combining targeted therapies in metastatic colorectal cancerNat Rev Clin Oncol200961273173319942926
   PubMed Web of Science ®Google Scholar